|
WO2020172720A1
|
|
Compositions and methods for treating oculopharyngeal muscular dystrophy (opmd)
|
|
WO2020077412A1
|
|
Methods for treating oculopharyngeal muscular dystrophy (opmd)
|
|
WO2019119036A1
|
|
Cd70 deficient cells, and methods and reagents for producing same
|
|
US2020190481A1
|
|
Adeno-Associated Virus (AAV) with Modified Phospholipase Domain
|
|
WO2018141025A1
|
|
Reagents for treatment of ocular diseases and conditions associated with neovascularisation and use thereof
|
|
AU2017377661A1
|
|
Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof
|
|
EP3512950A1
|
|
REAGENTS FOR PRODUCING T-CELLS WITH NON-FUNCTIONAL T-CELL RECEPTORS (TCRs) COMPOSITIONS COMPRISING SAME AND USE THEREOF
|
|
KR20190003756A
|
|
Reagents for treating hepatitis B virus (HBV) infection and uses thereof
|
|
AU2017250017A1
|
|
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
|
|
US2017002356A1
|
|
HBV treatment
|
|
CA2984512A1
|
|
Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
|
|
SG10201705518SA
|
|
Age-Related Macular Degeneration Treatment
|
|
AU2013225619A1
|
|
Pain treatment
|
|
CA2853613A1
|
|
Hbv treatment
|
|
WO2012109798A1
|
|
Hbv treatment
|
